We spend more than any nation on Earth on healthcare. We live shorter, sicker lives than almost all of them. Where is the money going — and who decides?
In 2024, U.S. healthcare spending hit $5.3 trillion — 18% of the entire economy. That's $15,474 for every man, woman, and child in the country, whether they saw a doctor that year or not. To put it in perspective: in 1970, per capita health spending was $353. That is a 2,005% increase in 45 years.
Growth is accelerating, not slowing. The 7.2% increase in 2024 was the highest consecutive two-year run since 1991–1992. The CMS projects healthcare will consume 20.3% of GDP by 2033 — one in five dollars the country produces, just on healthcare.
And yet the Commonwealth Fund's Mirror Mirror 2024 report — comparing 10 wealthy nations on 70 health metrics — ranked the U.S. dead last in health outcomes, access to care, and equity. The U.S. was the only clear outlier. Every other country, despite spending a fraction of what we spend, has found a way to meet its citizens' basic health needs.
The breakdown of U.S. healthcare spending tells a story of where power sits in this system. Hospital care alone consumed $1.63 trillion — the single largest piece, growing 8.9% in 2024. Physician and clinical services hit $1.1 trillion. Prescription drugs: $467 billion.
Private health insurance spending grew 8.8% to $1.64 trillion, the largest payer category. Medicare covered 66.6 million Americans at a cost of $1.1 trillion. Medicaid served 84.3 million people — down from a pandemic-era peak of 92.2 million after continuous enrollment provisions expired. Out-of-pocket spending hit $556 billion.
Meanwhile, hospitals spent $43 billion in 2025 just trying to collect payments insurers already owed. Nearly $18 billion went to overturning claims denials alone. The average hospital employed 64 staff solely for administrative and billing functions — roughly 6.5% of total hospital employment — just navigating insurance paperwork.
The United States doesn't just pay more for healthcare — it pays dramatically more for the drugs inside it. A 2024 RAND Corporation study analyzed prescription drug prices in 34 OECD nations and found U.S. prices averaged 2.78 times what other countries pay. For brand-name drugs specifically, that gap explodes: U.S. prices average 4.22 times what the same drugs cost elsewhere.
Insulin tells the starkest story. In 2022, the U.S. paid nearly 10 times more for insulin than the average across 33 comparison countries. More than 10 times higher than France and the UK. The drug has been around since 1921 — it is not new technology.
The reason? Unlike every other wealthy nation, the U.S. has no mechanism for government price negotiation on most drugs, no caps on what manufacturers can charge, and allows direct-to-consumer pharmaceutical advertising. The result: the U.S. accounts for 62% of global pharmaceutical sales revenue while representing just 24% of global prescription volume. We are the profit engine for the global drug industry.
Retail prescription drug spending increased 12.9% in 2024 — the fastest growing component of healthcare. GLP-1 drugs like Ozempic and Wegovy are accelerating this further.
The U.S. ranked last out of 10 wealthy nations in three of five categories in the 2024 Commonwealth Fund assessment: access to care, health outcomes, and equity. The country ranked 9th in administrative efficiency. Only in care process — screening rates, preventive services — did the U.S. perform competitively, ranking second.
Life expectancy at birth in the U.S. is 77.5 years — the shortest of all 10 nations in the study, and a gap that has grown since COVID. In 1980, U.S. life expectancy was nearly on par with peer nations. Decades of underinvestment in primary care, coverage gaps, and systemic inequity have eroded that standing.
Americans also lead peer nations in preventable and treatable deaths — deaths that could have been avoided with timely, effective care or prevention. Drug overdoses, gun-related deaths, and maternal mortality all contribute to America's historically poor outcomes ranking. The U.S. has the highest maternal mortality rate among comparable wealthy countries.
The conclusion from every major international health research body is the same: the U.S. is the only high-income country without universal coverage, and that single structural gap explains more of the performance deficit than any other factor.
| Metric | U.S. | Peer Avg | Status |
|---|---|---|---|
| Life Expectancy at Birth | 77.5 years | ~82 years | Last |
| Healthcare Spend Per Capita | $15,474 | ~$7,371 | 2× Peers |
| Preventable Deaths Rate | Highest | Significantly lower | Last |
| Maternal Mortality | Highest | Far lower | Last |
| Universal Coverage | No | Yes (all 9 peers) | Only nation |
| Access to Care Score | 10th of 10 | — | Last |
| Care Process (Prevention) | 2nd of 10 | — | 2nd |
| % Uninsured | 8.2% (28M) | ~0% | Only gap |
The American healthcare system does not fail everyone equally. The 28 million uninsured are disproportionately low-income, rural, and people of color. The states that refused Medicaid expansion — a political decision, not a financial one — are the states with the largest coverage gaps. Those residents are trapped in a zone too poor to afford private insurance and too "wealthy" (under pre-ACA thresholds) to qualify for Medicaid.
Beyond coverage: even the insured are not protected. An estimated one in four insured Americans is underinsured — meaning their deductibles and out-of-pocket costs are so high that seeking care creates financial hardship. The ACA out-of-pocket maximum in 2024 was $9,450 for a single adult. More than 40% of Americans spent at least $1,000 out of pocket in a single year on healthcare.
Primary care is collapsing under the strain. As of 2024, 53% of the U.S. primary care workforce is approaching retirement age. The U.S. has fewer general practitioners per capita than any of the peer nations studied. Sixteen percent of adults aged 19–64 used an ER for conditions treatable by a regular doctor — because they didn't have one.
Healthcare access in America has become a function of zip code, income, and employer. The wealthiest Americans receive some of the most advanced care in the world. Everyone else navigates a system designed around profit, not patients.
The political landscape around healthcare is shifting rapidly. Enhanced ACA subsidies that reduced marketplace premiums for millions of Americans expired at the end of 2025. Without legislative renewal, healthcare observers across the spectrum project the uninsured number will grow significantly in 2026.
At the same time, Congressional Republicans and the Trump administration's "One Big Beautiful Bill" proposed deep cuts to Medicaid. The Congressional Budget Office analysis projected the bill would result in millions more uninsured Americans by 2034. Democrats called this "gutting Medicaid." The debate continues.
On pharmaceuticals: the Inflation Reduction Act's Medicare Drug Price Negotiation Program — the first time in history Medicare could directly negotiate drug prices — was implemented for a first batch of 10 drugs. The results showed meaningful price reductions. Future expansion of that program is now politically contested.
Meanwhile, the Change Healthcare cyberattack in February 2024 exposed the fragility of America's centralized healthcare billing infrastructure, disrupting payment processing for hospitals and pharmacies nationwide — a reminder that a system built around billing efficiency, not patient care, carries unique systemic risks.
Healthcare spending is projected to reach 20.3% of GDP by 2033. Without structural reform, the system will continue consuming a growing share of the economy while delivering outcomes that trail countries that spend half as much per person.